News
BCAB
2.540
+12.89%
0.290
Bioatla, Inc.: Other definitive proxy statementsOpen document
Press release · 4d ago
Weekly Report: what happened at BCAB last week (0415-0419)?
Weekly Report · 6d ago
Weekly Report: what happened at BCAB last week (0408-0412)?
Weekly Report · 04/15 10:36
Buy Rating Affirmed for BioAtla on Strong Clinical Pipeline and Financial Stability
TipRanks · 04/10 23:05
Weekly Report: what happened at BCAB last week (0401-0405)?
Weekly Report · 04/08 10:39
GRIN, WOOF and MRNS are among after hour movers
On the Move GRIN, WOOF and MRNS are among after hour movers. Candel Therapeutics (CADL) and Petco Health and Wellness Company (WOOF) gain. HWH International (HWH) is among the losers.
Seeking Alpha · 04/04 21:29
Weekly Report: what happened at BCAB last week (0325-0329)?
Weekly Report · 04/01 10:38
BioAtla Price Target Maintained With a $12.00/Share by JMP Securities
Dow Jones · 03/28 14:45
JMP Securities Reiterates Market Outperform on BioAtla, Maintains $12 Price Target
Benzinga · 03/28 14:34
BioAtla Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/27 10:36
BioAtla Price Target Cut to $7.00/Share From $10.00 by HC Wainwright & Co.
Dow Jones · 03/27 10:36
HC Wainwright & Co. Maintains Buy on BioAtla, Lowers Price Target to $7
Benzinga · 03/27 10:26
Optimistic Outlook for BioAtla’s Pipeline Progression and Potential Partnerships
TipRanks · 03/27 10:06
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/27 05:20
BioAtla Q4 EPS $(0.56) Beats $(0.79) Estimate
Benzinga · 03/26 21:35
NCNO, OPI and MESO are among after hour movers
On the Move NCNO, OPI and MESO are among after hour movers. G-III Apparel Group and Bowman Consulting are among the losers. NCino, BMEA and BWMN were among the biggest gainers on the day.
Seeking Alpha · 03/26 20:42
BioAtla reports Q4 results
BioAtla reports Q4 results Mar. 26, 2024. Cash and cash equivalents as of December 31, 2023 were $111.5 million. The company expects to fund operations into the second half of 2025. Net loss for the quarter ended 2023 was $26.9 million.
Seeking Alpha · 03/26 20:03
*BioAtla 4Q Loss $26.9M >BCAB
Dow Jones · 03/26 20:02
BRIEF-BioAtla Q4 Net Income USD -26.925 Million
Reuters · 03/26 20:01
Press Release: BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights. CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) of 10 mg/kg. Company continues to make progress in its clinical programs. Cash balance of $111.5 million at year-end 2023.
Dow Jones · 03/26 20:01
More
Webull provides a variety of real-time BCAB stock news. You can receive the latest news about Bioatla, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BCAB
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.